August 2022 – Genprex

Genprex Announces U.S. Patent for REQORSA™ Immunogene Therapy in Combination with Immune Checkpoint Inhibitors to Treat Cancers

August 16, 2022Kalyn Dabbs Press Releases

Genprex Announces U.S. Patent for REQORSA™ Immunogene Therapy in Combination with Immune Checkpoint Inhibitors to Treat Cancers

Intellectual Property Protection for Therapeutic Combination in Acclaim-2 Phase 1/2 Clinical Trial

Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer

August 15, 2022Kalyn Dabbs Acclaim 2 Press Releases

Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer

Recommends Advancing Acclaim-1 to Increased Dose in Second Cohort of Phase 1 Portion of Trial

Designed and Secured by Barsec

Copyright ©2024 all rights reserved.
Home - Privacy Policy - Terms of Use